ATE375804T1 - Ribavirin-enthaltende vakzine - Google Patents

Ribavirin-enthaltende vakzine

Info

Publication number
ATE375804T1
ATE375804T1 AT01972379T AT01972379T ATE375804T1 AT E375804 T1 ATE375804 T1 AT E375804T1 AT 01972379 T AT01972379 T AT 01972379T AT 01972379 T AT01972379 T AT 01972379T AT E375804 T1 ATE375804 T1 AT E375804T1
Authority
AT
Austria
Prior art keywords
ribavirin
antigen
disclosed
containing vaccines
vaccines
Prior art date
Application number
AT01972379T
Other languages
English (en)
Inventor
Matti Sallberg
Catharina Hultgren
Original Assignee
Tripep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep Ab filed Critical Tripep Ab
Application granted granted Critical
Publication of ATE375804T1 publication Critical patent/ATE375804T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01972379T 2000-08-17 2001-08-15 Ribavirin-enthaltende vakzine ATE375804T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22576700P 2000-08-17 2000-08-17
US22917500P 2000-08-29 2000-08-29
US70554700A 2000-11-03 2000-11-03

Publications (1)

Publication Number Publication Date
ATE375804T1 true ATE375804T1 (de) 2007-11-15

Family

ID=27397520

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01972379T ATE375804T1 (de) 2000-08-17 2001-08-15 Ribavirin-enthaltende vakzine
AT07020248T ATE517184T1 (de) 2000-08-17 2001-08-15 Hcv ns3/4a kodierende nukleinsäure

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07020248T ATE517184T1 (de) 2000-08-17 2001-08-15 Hcv ns3/4a kodierende nukleinsäure

Country Status (12)

Country Link
US (1) US6960569B2 (de)
EP (3) EP2332574A1 (de)
JP (1) JP5175417B2 (de)
KR (2) KR100801123B1 (de)
CN (1) CN100400101C (de)
AT (2) ATE375804T1 (de)
AU (4) AU9215101A (de)
CA (1) CA2419418A1 (de)
DE (1) DE60130998T2 (de)
ES (1) ES2296803T3 (de)
PL (1) PL360990A1 (de)
WO (2) WO2002013855A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
EP1395262A4 (de) * 2001-06-15 2006-04-12 Ribapharm Corp Nucleosid-vakzine-adjuvantien
WO2004019878A2 (en) * 2002-08-27 2004-03-11 Compound Therapeutics, Inc. Adzymes and uses thereof
KR20050086843A (ko) * 2002-11-26 2005-08-30 트리펩 아베 증강인자 성분으로서의 ｃ형 간염 바이러스 비구조 단백질4ａ(ｎｓ4ａ)
US7419912B2 (en) 2004-04-01 2008-09-02 Cree, Inc. Laser patterning of light emitting devices
ES2294589T3 (es) * 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
ATE474587T1 (de) * 2004-09-29 2010-08-15 Univ Tulane Inhibitoren des hepatitis-c-virus
AU2012200012B8 (en) * 2004-09-29 2014-05-01 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
WO2008004992A2 (en) * 2005-05-25 2008-01-10 Tripep Ab Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil
CN101330928B (zh) * 2005-10-07 2012-11-14 西马生物医学计划公司 用于预防和治疗丙型肝炎的免疫刺激剂组合
ES2334472B1 (es) * 2006-06-09 2011-01-21 Proyecto De Biomedicina Cima, S.L. Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c.
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
EP2185195A2 (de) * 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
EP2233575A4 (de) * 2007-12-18 2012-12-26 Univ Peking Peoples Hospital Anti-hcv-impfstoff sowie herstellungsverfahren und verwendungen dafür
CN108148121B (zh) * 2018-03-06 2021-07-09 中美赛尔生物科技(广东)有限公司 丙型肝炎病毒抗原多肽组合物以及丙型肝炎病毒疫苗

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2933693A (en) 1957-05-03 1960-04-19 Lyle R Battersby Sensitivity control circuit
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6171782B1 (en) * 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5968775A (en) * 1987-11-18 1999-10-19 Chiron Corporation Hepatitis C virus infected cell systems
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US4950647A (en) 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0414475B1 (de) 1989-08-25 1997-12-10 Chiron Corporation Verfahren zur HCV-Züchtung in Zell-Linien aus B- oder T-Lymphozyten
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
WO1991004262A1 (en) * 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
HU217025B (hu) 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
ATE270326T1 (de) * 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus
CZ282573B6 (cs) 1990-08-10 1997-08-13 Chiron Corporation Způsob detekce HCV sekvence, souprava a reakční činidlo pro detekci HCV
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
EP0842947B2 (de) 1990-11-08 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Asialoglykoproteine des Hepatitis C Virus
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
SK284205B6 (sk) 1991-05-08 2004-10-05 Chiron Corporation Prirodzene sa nevyskytujúca nukleová kyselina, spôsob tvorby hybridizačného produktu a spôsob detekcie genotypov HCV
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
WO1993000365A2 (en) 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5795714A (en) 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
DE4239311C2 (de) 1992-11-23 1996-04-18 Guehring Joerg Dr Bohrer, insbesondere Spitzbohrwerkzeug mit austauschbarem Schneideinsatz
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
EP0651807B1 (de) * 1993-04-27 2007-09-12 N.V. Innogenetics S.A. Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
DK0789590T3 (da) 1994-09-23 2002-11-04 Zonagen Inc Chitosaninduceret immunforstærkning
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
WO1996013590A2 (en) * 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
FR2730935A1 (fr) * 1994-12-21 1996-08-30 Vacsyn Sa Vaccin presentant une immunogenicite accrue
US5932556A (en) * 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
WO1996028162A1 (en) 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
RU2186569C2 (ru) * 1996-01-23 2002-08-10 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
EP0937159A4 (de) 1996-02-08 2004-10-20 Affymetrix Inc Speziesbestimmung und phenotypische charakterisierung von mikroorganismen auf der basis eines chips
EP2332958B1 (de) 1996-02-09 2016-04-20 Cornell Research Foundation, Inc. Detektion von Unterschieden in der Sequenz von Nukleinsäuren mittels der Ligasedetektionsreaktion und adressierbaren Arrays
US6514731B1 (en) * 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
AU717542B2 (en) * 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
EP2298900A1 (de) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
IL129126A0 (en) 1996-10-16 2000-02-17 Icn Pharmaceuticals Monocyclic l-nucleosides analogs and uses thereof
ATE271063T1 (de) 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
IL119833A (en) * 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
AU736075B2 (en) 1997-01-17 2001-07-26 Icn Pharmaceuticals, Inc. Cytokine related treatments of disease
DK0969862T3 (da) 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US6211338B1 (en) * 1997-11-28 2001-04-03 Schering Corporation Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
BRPI9909678B8 (pt) * 1998-04-17 2021-05-25 Fujirebio Europe N V aperfeiçoados ensaios de imunodiagnóstico usando agentes redutores
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20020187945A1 (en) * 1999-01-29 2002-12-12 Robert Tam Modulation of immune response by ribavirin
SK10092001A3 (sk) 1999-01-29 2002-02-05 Icn Pharmaceuticals, Inc. Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu
CA2390082C (en) 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
DK1354204T4 (da) * 2000-06-15 2010-06-14 Novartis Vaccines & Diagnostic HCV-antigen/antistof-kombinationssay
JP5175417B2 (ja) 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치
CN114223241A (zh) 2019-08-14 2022-03-22 三星电子株式会社 用于在无线通信系统中执行rrm测量的方法和终端

Also Published As

Publication number Publication date
EP1311289A2 (de) 2003-05-21
AU2006203358B2 (en) 2008-07-17
EP1947185B1 (de) 2011-07-20
AU2001290178A1 (en) 2002-02-25
EP2332574A1 (de) 2011-06-15
KR100801123B1 (ko) 2008-02-05
KR20070114209A (ko) 2007-11-29
AU2001292151B2 (en) 2006-05-04
PL360990A1 (en) 2004-09-20
DE60130998T2 (de) 2008-07-17
WO2002014362A2 (en) 2002-02-21
CN1469755A (zh) 2004-01-21
DE60130998D1 (de) 2007-11-29
EP1947185A1 (de) 2008-07-23
AU2001292151C1 (en) 2002-02-25
ES2296803T3 (es) 2008-05-01
JP2004506018A (ja) 2004-02-26
JP5175417B2 (ja) 2013-04-03
EP1311289B1 (de) 2007-10-17
AU9215101A (en) 2002-02-25
CN100400101C (zh) 2008-07-09
WO2002013855A2 (en) 2002-02-21
WO2002014362A3 (en) 2003-11-13
KR20030024876A (ko) 2003-03-26
ATE517184T1 (de) 2011-08-15
AU2006203358A1 (en) 2006-08-31
CA2419418A1 (en) 2002-02-21
US20040092730A1 (en) 2004-05-13
WO2002013855A3 (en) 2003-01-09
US6960569B2 (en) 2005-11-01

Similar Documents

Publication Publication Date Title
DE60130998D1 (de) Ribavirin-enthaltende vakzine
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
ATE309268T1 (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
ATE485056T1 (de) Verbesserte impfstoffe
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
ATE326236T1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
EA200401405A1 (ru) Модифицированный осповакцинный вирус анкара для вакцинации новорожденных
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
DE69935721D1 (de) Kälte-adaptierte pferde influenza-viren
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
EP1256348A4 (de) Heilmittel gegen hepatitis
DE60115051D1 (de) Immunologische adjuvans verbindungen
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
EA200301151A1 (ru) Вакцина против натуральной оспы
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
EA200400534A1 (ru) Стимуляция тимозином генетической иммунизации
ATE467424T1 (de) Escape-mutanten des newcastle-disease-virus als marker-vakzine
TH45979A (th) วัคซีนพอกซ์ไวรัสรีคอมบิแนนท์ต่อเซอร์โคไวรัสของหมู

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311289

Country of ref document: EP